Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan
Investigative Ophthalmology & Visual Science · 2024
DOI: 10.1167/iovs.65.6.19 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2024. Written by Hou-Ren Tsai and 8 co-authors. Institution: Department of Ophthalmology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Retinal Vein Occlusion, Dipeptidyl-Peptidase IV Inhibitors. Cited 7 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Purpose
The purpose of this study was to evaluate the risk of newly diagnosed retinal vein occlusion (RVO) in patients with type 2 diabetes (T2D) using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) compared to dipeptidyl peptidase-4 inhibitors (DPP-4i).
Methods
Claims data from the National Health Insurance Research Database of Taiwan were used in this nationwide retrospective cohort study. A target trial emulation framework was applied. Patients with T2D with no prior diagnosis of RVO who had newly commenced treatment with SGLT-2i or DPP-4i between May 1, 2016, and December 31, 2020, were included. Potential systematic differences in baseline characteristics between the paired groups were controlled using stabilized inverse probability of treatment weighting. The outcome of interest was incident RVO. The hazard ratio (HR) for SGLT-2i compared with that of DPP-4i was estimated using a Cox regression model.
Results
Data from 123,567 and 578,665 patients receiving SGLT-2i and DPP-4i, respectively, were analyzed. The incidence of RVO was lower in patients newly receiving SGLT-2i (0.59 events per 1000 person-years) compared to those receiving DPP-4i (0.77 events per 1000 person-years) over a mean follow-up of 1.61 years. SGLT-2i users had a significantly lower risk of developing RVO compared with DPP-4i users (HR = 0.76, 95% confidence interval [CI] = 0.59-0.98). In the individual outcome analysis, SGLT-2i use was significantly associated with a lower risk of branch RVO (HR = 0.71, 95% CI = 0.52-0.96), but not central RVO (HR = 0.84, 95% CI = 0.57-1.24).
Conclusions
The risk of developing RVO was lower in patients with T2D receiving SGLT-2i compared with that in those receiving DPP-4i.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
- Health Information Center, Tzu Chi University, Hualien, Taiwan.
- School of Medicine, Tzu Chi University, Hualien, Taiwan.
- Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
- Department of Physical Medicine and Rehabilitation, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
- Center for Aging and Health, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Cite
APA
Tsai, H. R., Lin, Y. J., Yeh, J. I., Lin, S. M., Liu, P. P., Chang, Y. C., Lee, Y. C., Loh, C. H., & Huang, H. K. (2024). Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.65.6.19
Vancouver
Tsai HR, Lin YJ, Yeh JI, Lin SM, Liu PP, Chang YC, et al. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan. Investigative Ophthalmology & Visual Science. 2024. doi:10.1167/iovs.65.6.19
BibTeX
@article{Tsai2024,
author = {Tsai, Hou-Ren and Lin, Yu-Jie and Yeh, Jih-I and Lin, Shu-Man and Liu, Peter Pin-Sung and Chang, Yung-Ching and Lee, Yuan-Chieh and Loh, Ching-Hui and Huang, Huei-Kai},
title = {Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
doi = {10.1167/iovs.65.6.19}
}
EUVIMED